A Comparison of NETSPOT Imaging Versus F-FDG-PET in Head and Neck Cancer Patients

Patients meeting inclusion criteria will be consented at the time of scheduling. All patients
will undergo 18F-FDG-PET/CT per established protocol. Following 18F-FDG-PET/CT, the patient
will undergo NETSPOT imaging with the AAA-provided dose. These scans will be performed no
less than 8 hours, no more than 7 days apart. For patients undergoing same-day imaging,
NETSPOT imaging will be performed prior to 18F-FDG-PET/CT. Following imaging, both
18F-FDG-PET/CT and NETSPOT imaging will be compared by trained neuroradiologists for SUV
values and concordance with known sites of disease. Biopsies will be performed as is standard
to verify all sites of primary or metastatic disease. Patients with oropharyngeal tumors will
have HPV testing performed via the standard of care surrogate marker p16. Patients with
p16-positive tumors will be recorded and analyzed separately for the above measures. Patients
will be followed for a total of 1 year after the study and outcomes of overall survival,
disease-free survival, presence and site of recurrence and development of metastatic disease
will be recorded. All gathered data will be compared between reported 18F-FDG-PET/CT and
NETSPOT imaging for true positive, true negative, positive predictive value and negative
predictive value of patient groups.

Inclusion Criteria:

Patients with suspected or diagnosed HNSCC undergoing planned 18F FDG PET/CT at the time of
primary diagnosis or after completion of treatment.

Exclusion Criteria:

Inability to undergo 18F-FDG-PET/CT imaging due to medical comorbidities